SEngine Precision Medicine brings the latest advances in cancer research and treatment to the fight against cancer. With a focus on functional screening, genomics, robotics, cancer organoid cultures, and bioinformatics, SEngine Precision Medicine is providing invaluable data to oncologists and realizing the promise of precise, less toxic and more effective therapies to cancer patients. The accumulation of data is essential to pharmaceutical companies to accelerate the success of cancer treatments.
SEngine is CLIA certified to receive your sample today.
SEngine is CLIA certified to receive your sample today.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $24.1M
Founded date: 2015
Founders name: Lonnie Bookbinder, MBA, PhD
Founders Related Locations: United States, California, Davis; United States, Washington, Seattle
Investors 1
| Date | Name | Website |
| - | WRF Capita... | wrfseattle... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.08.2022 | Series A | $19M | - |
| 03.10.2019 | Series A | $5.1M | - |
Mentions in press and media 14
| Date | Title | Description |
| 18.04.2023 | Protein design to precision health: Vote for Health Innovation of the Year at the GeekWire Awards | Finalists for the 2023 GeekWire Health Innovation of the Year. This year’s nominees for the Health Innovation of the Year at the GeekWire Awards showcase a wide range of innovations from companies focused on diagnostics, therapeutics, digit... |
| 10.08.2022 | Fred Hutch spinout lands $10M for precision test to guide cancer treatment, develop drugs | SEngine CEO and chief scientific officer Carla Grandori. (SEngine Photo) Seattle startup SEngine Precision Medicine has raised $10 million to propel drug discovery and development and advance its test that tailors drugs to cancer patients. ... |
| 28.07.2022 | SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments | SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform tha... |
| 09.07.2021 | Biotech startup using AI to take guesswork out of cancer drug selection raises $70M | From the moment cancer is diagnosed, the clock starts ticking. Early treatment can lead to better outcomes, but physicians must first choose a drug. It can take months to assess how the selected drug is working, which takes time away from a... |
| 14.08.2020 | Canada’s Atomwise secures 163M CAD in Series B funding | The AI-driven drug discovery platform was founded in 2012 by Abraham Heifets, Alexander Levy and Dr. Izhar Wallach and was earlier known as Chematria. It was initially a part of University of Toronto’s incubator before associating with Y Co... |
| 02.10.2019 | Fred Hutch spinout SEngine raises $5.1M to test cancer treatment drugs against a patient’s tumors | SEngine tests how safe and effective various cancer drugs are against a patient’s tumor. Each well in the tray pictured above could hold a tiny version of a tumor and a unique drug or combination of drugs. (SEnginge Photo) Seattle startup S... |
| 02.10.2019 | SEngine Precision Medicine Raises $5.1M in Series A Funding | SEngine Precision Medicine, a Seattle, Wash.-based oncology company, closed a $5.1m in Series A funding. The round, which brings total funding to date to more than $9m, was led by the Bangarang Group with participation from various family o... |
| 03.06.2019 | What’s health tech’s evolving role in cancer treatment? Learn more at the CONVERGE conference in Philadelphia! | Through a mix of provocative conversations, interactive networking, and a showcase of the hottest startups, you’ll get actionable insight into how AI, big data, precision medicine and more are transforming cancer treatment. Among the highli... |
| 09.05.2019 | Don’t miss this innovation in cancer treatment conference in Philadelphia | A panel discussion will explore how precision medicine can be the key to population health. Experts from Cancer Treatment Centers of America, Color and other organizations will talk about the synergies between precision medicine and populat... |
| 29.10.2018 | SEngine Precision Medicine raises $3M, adds former Fred Hutch president to board | A SEngine Precision Medicine employee in the company’s lab. (SEngine Precision Medicine Photo) SEngine Precision Medicine, a startup working to personalize cancer treatment, has raised $3 million in new funding and added former Fred Hutchin... |
Show more